INTERFERON BETA-1A

( DrugBank: Interferon beta-1a / KEGG DRUG: Interferon beta-1a )


5 diseases
IDDisease name (Link within this page)Number of trials
96Crohn disease1
97Ulcerative colitis1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 302 / Drugs : 231 - (DrugBank : 32) / Drug target genes : 16 - Drug target pathways : 67 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

26. HTLV-1-associated myelopathy


Clinical trials : 33 / Drugs : 60 - (DrugBank : 31) / Drug target genes : 33 - Drug target pathways : 113 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,888 / Drugs : 1,678 - (DrugBank : 247) / Drug target genes : 193 - Drug target pathways : 234 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

97. Ulcerative colitis


Clinical trials : 3,566 / Drugs : 2,369 - (DrugBank : 339) / Drug target genes : 210 - Drug target pathways : 245 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries